Miracle drug naltrexone?—Not more effective for fibromyalgia than placebo

被引：0

作者：

Gehrke-Beck S. ^{[1
]}

机构：

[1] Institut für Allgemeinmedizin, Charité – Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, Berlin

来源：

Zeitschrift für Allgemeinmedizin | 2024年 / 100卷 / 6期

关键词：

D O I：

10.1007/s44266-024-00242-4

中图分类号：

学科分类号：

摘要：

[No abstract available]

引用

页码：291 / 292

页数：1

共 5 条

[1]

Paschke L., Dreyer N., Worm M., Klinger R., Can open label placebos improve pain and gluten tolerance via open label placebos in fibromyalgia patients? A study protocol for a randomised clinical trial in an outpatient centre, BMJ Open, 13, 10, (2023)

[2]

O'Kelly B., Vidal L., McHugh T., Woo J., Avramovic G., Lambert J.S., Safety and efficacy of low dose naltrexone in a long covid cohort

[3]

an interventional pre-post study, Brain Behav Immun Health, 24, (2022)

[4]

Tamariz L., Bast E., Klimas N., Palacio A., Low-dose Naltrexone Improves post-COVID-19 condition Symptoms, Clin Ther, 46, 3, pp. e101-e106, (2024)

[5]

Naik H., Cooke E., Boulter T., Dyer R., Bone J.N., Tsai M., Cristobal J., McKay R.J., Song X., Nacul L., Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia, BMJ Open, 14, 5, (2024)

← 1 →